- Home
- BNAI vs APRE Comparison
BNAI vs APRE Comparison
Compare BNAI & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNAI
- APRE
- Stock Information
- Founded
- BNAI 2018
- APRE 2006
- Country
- BNAI United States
- APRE United States
- Employees
- BNAI N/A
- APRE N/A
- Industry
- BNAI
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BNAI
- APRE Health Care
- Exchange
- BNAI NYSE
- APRE Nasdaq
- Market Cap
- BNAI 15.7M
- APRE 13.5M
- IPO Year
- BNAI N/A
- APRE 2019
- Fundamental
- Price
- BNAI $0.33
- APRE $1.87
- Analyst Decision
- BNAI Strong Buy
- APRE Strong Buy
- Analyst Count
- BNAI 1
- APRE 2
- Target Price
- BNAI $6.00
- APRE $15.50
- AVG Volume (30 Days)
- BNAI 358.4K
- APRE 21.0K
- Earning Date
- BNAI 05-25-2025
- APRE 05-13-2025
- Dividend Yield
- BNAI N/A
- APRE N/A
- EPS Growth
- BNAI N/A
- APRE N/A
- EPS
- BNAI N/A
- APRE N/A
- Revenue
- BNAI $99,790.00
- APRE $1,502,581.00
- Revenue This Year
- BNAI $189.69
- APRE N/A
- Revenue Next Year
- BNAI $2,400.00
- APRE N/A
- P/E Ratio
- BNAI N/A
- APRE N/A
- Revenue Growth
- BNAI 125.10
- APRE 157.63
- 52 Week Low
- BNAI $0.30
- APRE $1.85
- 52 Week High
- BNAI $8.43
- APRE $6.70
- Technical
- Relative Strength Index (RSI)
- BNAI 34.09
- APRE 26.70
- Support Level
- BNAI $0.36
- APRE $2.17
- Resistance Level
- BNAI $0.40
- APRE $2.30
- Average True Range (ATR)
- BNAI 0.03
- APRE 0.17
- MACD
- BNAI 0.00
- APRE -0.01
- Stochastic Oscillator
- BNAI 16.67
- APRE 2.50
About BNAI BRAND ENGAGEMENT NETWORK INC
Brand Engagement Network Inc is an innovative AI platform provider, designed to interface with emerging technologies, including blockchain, the Internet of Things, and cloud computing, that drive digital transformation across various industries and provide businesses with an unparalleled competitive edge. BEN offers a suite of configured and customizable applications, including natural language processing, anomaly detection, encryption, recommendation engines, sentiment analysis, image recognition, personalization, and real-time decision-making.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.